Nurix Therapeutics, Inc.
NRIXNasdaq
$23.12
↑ +0.2%Jul 17 close · end-of-day
Price
1Y↑ +86.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.6B
Enterprise Value
$2.5B
P/E
—
P/S
69.9
P/B
6.4
EV/EBITDA
—
PEG
—
FCF Yield
-11.9%
Dividend Yield
0.0%
Revenue (TTM)
$36.8M
Net Income (TTM)
-$341.4M
Free Cash Flow (TTM)
-$304.5M
Gross Margin
—
Operating Margin
-982.4%
Net Margin
-928.4%
ROE
-84.8%
ROIC
-85.2%
Debt / Equity
—
Net Cash
$67.7M
Return 1Y
+91.2%
Company profile
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies. NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy, is in Phase 1 clinical trials for gynecologic cancers, including ovarian, endometrial, and cervical cancer.
- CEO
- Arthur T. Sands
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 300
- Headquarters
- California
- Website
- nurixtx.com
Management & directors
- Ring ChristineChief Legal Officer
- Hansen GwennChief Scientific Officer
- Van Houte HansChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
NRIX Q2 2026 Earnings
Period ends 2026-05-31
MetricActualYoY
Revenue$9.0M↓ -79.5%
Diluted EPS-$0.81↑ +55.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $17.8M | $29.8M | $38.6M | $77.0M | $54.5M | $84.0M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$65.0M | -$117.9M | -$183.9M | -$155.1M | -$213.0M | -$285.7M |
| Net income | -$43.2M | -$117.2M | -$180.4M | -$143.9M | -$193.6M | -$264.5M |
| Diluted EPS | — | -$2.73 | -$3.71 | -$2.65 | -$2.88 | -$3.05 |
| Operating cash flow | -$80,000.00 | -$84.4M | -$159.8M | -$81.4M | -$172.6M | -$249.5M |
| Free cash flow | -$4.6M | -$90.0M | -$172.1M | -$89.8M | -$181.9M | -$263.5M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -364.7% | -396.3% | -476.0% | -201.4% | -390.5% | -340.2% |
| Net margin | -242.7% | -393.9% | -466.9% | -187.0% | -354.9% | -314.9% |
| Line item | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.6M | $13.3M | $18.5M | $44.1M | $7.9M | $13.6M | $6.3M | $9.0M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$54.6M | -$64.7M | -$62.9M | -$48.3M | -$91.4M | -$83.1M | -$92.5M | -$94.2M |
| Net income | -$49.0M | -$58.5M | -$56.4M | -$43.5M | -$86.4M | -$78.2M | -$87.2M | -$89.5M |
| Diluted EPS | -$0.67 | -$0.74 | -$0.67 | -$0.52 | -$1.03 | -$0.83 | -$0.79 | -$0.81 |
| Operating cash flow | -$42.2M | -$48.8M | -$61.1M | -$63.2M | -$57.4M | -$67.8M | -$71.9M | -$96.6M |
| Free cash flow | -$44.5M | -$50.9M | -$64.6M | -$65.8M | -$60.1M | -$73.0M | -$73.0M | -$98.5M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -433.8% | -486.7% | -340.7% | -109.7% | -1157.7% | -612.0% | -1479.4% | -1041.7% |
| Net margin | -388.9% | -440.7% | -305.4% | -98.7% | -1094.8% | -576.1% | -1394.3% | -990.1% |
Company news
Jul 9, 2026
Jul 1, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-02 | Ring Christine· Chief Legal Officer | Sale | 11,008 | $23.56 | $259,366.09 | filing |
| 2026-07-02 | Ring Christine· Chief Legal Officer | Option exercise | 5,787 | $8.72 | $50,462.64 | filing |
| 2026-07-02 | Ring Christine· Chief Legal Officer | Option exercise | 5,221 | $1.86 | $9,711.06 | filing |
| 2026-06-25 | Ring Christine· Chief Legal Officer | Sale | 28,935 | $20.06 | $580,505.54 | filing |
| 2026-06-25 | Ring Christine· Chief Legal Officer | Option exercise | 15,602 | $8.72 | $136,049.44 | filing |
| 2026-06-25 | Hansen Gwenn· Chief Scientific Officer | Sale | 5,394 | $20.00 | $107,880.00 | filing |
| 2026-06-25 | Ring Christine· Chief Legal Officer | Option exercise | 13,333 | $7.26 | $96,797.58 | filing |
| 2026-06-02 | Ring Christine· Chief Legal Officer | Sale | 8,148 | $16.60 | $135,252.73 | filing |
| 2026-06-02 | Ring Christine· Chief Legal Officer | Option exercise | 3,422 | $1.86 | $6,364.92 | filing |
| 2026-05-05 | van Houte Hans· Chief Financial Officer | Sale | 13,473 | $16.58 | $223,323.06 | filing |
| 2026-05-05 | van Houte Hans· Chief Financial Officer | Sale | 582 | $17.18 | $9,995.91 | filing |
| 2026-05-04 | Ring Christine· Chief Legal Officer | Sale | 8,148 | $16.96 | $138,209.64 | filing |
| 2026-05-01 | Ring Christine· Chief Legal Officer | Sale | 5,394 | $16.76 | $90,406.68 | filing |
| 2026-04-30 | Hansen Gwenn· Chief Scientific Officer | Sale | 3,214 | $16.65 | $53,497.99 | filing |
| 2026-04-30 | Ring Christine· Chief Legal Officer | Sale | 3,214 | $16.65 | $53,497.99 | filing |
| 2026-04-30 | van Houte Hans· Chief Financial Officer | Sale | 2,388 | $16.65 | $39,748.98 | filing |
| 2026-04-30 | van Houte Hans· Chief Financial Officer | Option exercise | 2,000 | $0.00 | $0.00 | filing |
| 2026-04-30 | van Houte Hans· Chief Financial Officer | Option exercise | 3,750 | $0.00 | $0.00 | filing |
| 2026-04-30 | van Houte Hans· Chief Financial Officer | Option exercise | 2,858 | $0.00 | $0.00 | filing |
| 2026-04-30 | Ring Christine· Chief Legal Officer | Option exercise | 2,000 | $0.00 | $0.00 | filing |
| 2026-04-30 | Ring Christine· Chief Legal Officer | Option exercise | 3,750 | $0.00 | $0.00 | filing |
| 2026-04-30 | Ring Christine· Chief Legal Officer | Option exercise | 2,858 | $0.00 | $0.00 | filing |
| 2026-04-30 | Hansen Gwenn· Chief Scientific Officer | Option exercise | 2,000 | $0.00 | $0.00 | filing |
| 2026-04-30 | Hansen Gwenn· Chief Scientific Officer | Option exercise | 3,750 | $0.00 | $0.00 | filing |
| 2026-04-30 | Hansen Gwenn· Chief Scientific Officer | Option exercise | 2,858 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.